Specialty Pharmacy

Combination of sofosbuvir and simeprevir may have an unexpected side effect in HCV therapy.

Roflumilast has been found to help prevent flare-ups associated with COPD.

Experimental DMARD may be clinically beneficial for active rheumatoid arthritis treatment.

HIV-1-associated neurocognitive disorders afflict almost half of all patients with HIV.

The Institute for Safe Medication Practices (ISMP) is alerting pharmacists about the risks of mixing up idarucizumab (Praxbind) with idarubicin.

Serum levels may determine impact of anti-tumor necrosis factor drugs.

Recent news in cancer drug development.

Lawsuits challenge access denials to curative hepatitis C drugs among incarcerated individuals infected with the disease.

Study may lead to vaccines that force an immune response.

Researchers seek to determine which side effects will be experienced by different patient groups.

Top stories of the week on Specialty Pharmacy Times.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses how the ACA has impacted the specialty landscape.

Some patients with MS received a benefit from natalizumab involving the reduction of relapses and new MRI lesions.

Prescription drug use increased significantly among persons aged 40 to 64 years and among those age 65 and older.

People living in poorer areas less likely to receive screening.

The US Senate has launched a bipartisan investigation into prescription drug pricing, targeting Valeant, Turing Pharma, Retrophin, and Rodelis in particular.

Gilead's Genvoya is the first TAF-based regimen approved by the FDA.

Terms like revolutionary or miracle cause confusion for readers.

Biofilm proteins show promise in treatment of gastrointestinal disorders.

Nucala is for use with other asthma drugs for the maintenance of patients 12 years and older.

Liver disease experts suggest how to prioritize the treatment of different HCV patient groups.

Intensity modulated radiation therapy shows less intense lung toxicity for more tolerable chemotherapy.

Guidance addresses the development of clinical trials to test novel antiretroviral drugs for the treatment of HIV.

A 1961 Oklahoma Board of Pharmacy statute is just now causing tension between pharmacists and physicians.

Keytruda has already been approved for metastatic non-small cell lung cancer and metastatic melanoma.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

There are currently no approved treatments for tenosynovial giant cell tumors.

Leading online and digital news source responds to recent news reports, distinguishes between high touch specialty pharmacies and organizations that offer products without other support important to those needing complex care.